1. Volume 59, Issue 1, Pages 81-87 (January 2011)
Prostate Cancer Detection in the “Grey Area” of Prostate-Specific Antigen Below 10 ng/ml: Head-to-Head Comparison of the Updated PCPT Calculator and Chun’s Nomogram, Two Risk Estimators Incorporating Prostate Cancer Antigen 3 
Sisto Perdonà, Vitor Cavadas, Giuseppe Di Lorenzo, Rocco Damiano, Gennaro Chiappetta, Paola Del Prete, Renato Franco, Giuseppina Azzarito, Stefania Scala, Claudio Arra, Marco De Sio, Riccardo Autorino 
European Urology 
Volume 59, Issue 1, Pages (January 2011)
DOI: /j.eururo
Copyright © 2010 European Association of Urology Terms and Conditions

2. Fig. 1
Probability of positive biopsy for different ranges of the prostate cancer antigen 3 score (according to previously published cut-offs).
PCA3=prostate cancer antigen 3; PCa=prostate cancer.
European Urology  , 81-87DOI: ( /j.eururo )
Copyright © 2010 European Association of Urology Terms and Conditions

3. Fig. 2
Receiver operating characteristic curves for the Prostate Cancer Prevention Trial risk calculator, Chun’s nomogram, prostate cancer antigen 3, and prostate-specific antigen for (A) the entire cohort, (B) initial biopsy, and (C) repeat biopsy.
PCPT=Prostate Cancer Prevention Trial; PCA3=prostate cancer antigen 3; PSA=prostate-specific antigen.
European Urology  , 81-87DOI: ( /j.eururo )
Copyright © 2010 European Association of Urology Terms and Conditions

4. Fig. 3
Calibration plots depicting the agreement between predicted and observed probabilities of positive biopsy for the Prostate Cancer Prevention Trial risk calculator and Chun’s nomogram for (A) the entire cohort, (B) initial biopsy, and (C) repeat biopsy.
PCPT=Prostate Cancer Prevention Trial.
European Urology  , 81-87DOI: ( /j.eururo )
Copyright © 2010 European Association of Urology Terms and Conditions

5. Fig. 4
Decision curve analysis for positive biopsy prediction by Prostate Cancer Prevention Trial risk calculator and Chun’s nomogram for (A) the entire cohort, (B) initial biopsy, and (C) repeat biopsy in the range of 10–40% threshold probability. The bottom table displays net benefit and reduction in avoidable biopsies for each of the two risk estimators compared to the “treat all” strategy of performing biopsy on every patient for different threshold probabilities in the same range for the entire cohort.
PCPT=Prostate Cancer Prevention Trial.
European Urology  , 81-87DOI: ( /j.eururo )
Copyright © 2010 European Association of Urology Terms and Conditions